Oxford Nanopore Technologies non-executive director Adrian Hennah has bought 24,000 of the company's shares on the London Stock Exchange at £2.164 each, a total outlay of £51,936.

What was announced

On 12 October 2026 Oxford Nanopore Technologies plc (LSE:ONT) published a notification of a transaction by a person discharging managerial responsibilities (PDMR) under the UK Market Abuse Regulation. The PDMR is Adrian Hennah, a non-executive director of the company.

The transaction is described as a "Purchase of shares" in the company's ordinary shares of £0.0001 each (ISIN GB00BP6S8Z30). It is an open-market purchase of existing shares. It is not an award under an incentive plan, an option exercise or a subscription for new shares.

The deal in numbers

  • Shares bought: 24,000 ordinary shares.
  • Price: £2.1640 per share.
  • Aggregate value: £51,936.00.
  • Date: 12 October 2026.
  • Venue: the London Stock Exchange (venue code XLON).

Who is Adrian Hennah?

Oxford Nanopore announced Hennah's appointment as an independent non-executive director in June 2021, with effect from 24 June 2021. At the time the company said it expected him to become chair of its Audit Committee later in 2021.

He began his career at PwC, in audit and consultancy, and at the German regional bank Stadtsparkasse Köln. He then spent 18 years in senior management and finance roles at GlaxoSmithKline, before serving as chief financial officer of Invensys, of Smith & Nephew and, for seven years, of Reckitt Benckiser.

He has been a non-executive director of Unilever PLC since 1 November 2021, chair of its Audit Committee since 2022 and a member of its Nominating and Corporate Governance Committee since 2024. He is also a non-executive director of J Sainsbury plc and an independent member of the Council of Imperial College London. His past roles include executive director of Reckitt Benckiser Group (2013–2020) and non-executive director of RELX (2011–2020), where he chaired the Audit Committee.

Company background

Oxford Nanopore sells nanopore sequencing technology, in which DNA or RNA molecules pass through tiny protein channels to be read in real time. Its product range covers sample preparation, flow cells and sequencing devices, and analysis software, used in areas such as microbial genomics, human genomics and cancer research.

In its interim results published on 19 August 2026, the company reported first-half revenue of £116.7 million, up 10.5% on a reported basis and 12.3% at constant currency. Gross margin rose to 62.2% from 58.2%, and the adjusted EBITDA loss narrowed to £22.1 million from £48.3 million a year earlier. Cash, cash equivalents and other liquid investments were £234.5 million at 30 June 2026, down from £302.8 million at the end of 2025.

The company said China revenue fell 15.7% in the half and cited continued disruption in the Middle East. Its own guidance for 2026, excluding a $20 million non-recurring licensing payment, is constant-currency revenue growth of 16–20% and a gross margin of about 62%. It targets adjusted EBITDA breakeven in 2027 and positive free cash flow in 2028.